Release Date: 17/08/10 18:39 Summary: Appendix 3B - Exercise of Performance Rights Price Sensitive: No Download Document 169.69KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%